Researchers assessed the safety and efficacy of febuxostat dose escalation among patients with gout according to hyperuricemia clinical subtype. Among patients with gout, those with combined subtype hyperuricemia exhibited a lower response to febuxostat vs patients with overload or underexcretion subtypes.